| Entries |
| Document | Title | Date |
|---|
| 20080200442 | Compositions and Methods for Treating, Reducing, Ameliorating, or Preventing Infections of the Ear or Upper Respiratory Tract - Compositions for treating, reducing, ameliorating, or preventing infection of an ear or upper respiratory tract comprise a fluroquinolone having Formula I, II, or III. Methods for treating, reducing, ameliorating, or preventing such infection use such compositions. Such compositions and methods can be effective against certain antibiotic-resistant microbial pathogens found in such infection. | 08-21-2008 |
| 20080207581 | Methods and systems for coating a surface - A coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may include quaternary ammonium moieties. In some embodiments, a method may include applying a coating to a surface. The coating may be antimicrobial. A coating may include antimicrobial bridged polycyclic compounds. Bridged polycyclic compounds may include quaternary ammonium compounds. Bridged polycyclic compounds based coating systems may impart self-cleaning properties to a surface. | 08-28-2008 |
| 20080234246 | ANALOGS OF ANSAMYCIN AND PHARMACEUTICAL COMPOSITIONS THEREOF - Analogs of geldanamycin (an ansamycin), pharmaceutical formulations comprising such analogs, and methods of use (e.g., treating tumors). | 09-25-2008 |
| 20080255079 | Therapeutic Use of Nefopam and Analogues Thereof - Nefopam or an analogue thereof is useful in the treatment of a syndrome characterized by chronic pain and fatigue. | 10-16-2008 |
| 20080255080 | Hydroquinone Ansamycin Formulations - Pharmaceutical compositions of hydroquinone geldanamycin analogs, and uses of such compositions, are provided. | 10-16-2008 |
| 20080261938 | Tetracyclic Indole Derivatives as Antiviral Agents - The present invention relates to tetracyclic indole compounds of formula (I); wherein R | 10-23-2008 |
| 20080275018 | ANTIBACTERIAL AMIDE-MACROCYCLES V - The invention relates to antibacterial amide-macrocycles of formula (I), in which R | 11-06-2008 |
| 20080300231 | Antibacterial amide macrocycles VI - The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular of bacterial infections. | 12-04-2008 |
| 20080306040 | Antibacterial amide macrocycles VII - The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infections. | 12-11-2008 |
| 20090029960 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS - The invention relates to novel macrocyclic compounds of the formula | 01-29-2009 |
| 20090042847 | 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN POLYMORPHS AND FORMULATIONS - Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxy-geldanamycin (17-AAG). | 02-12-2009 |
| 20090048222 | Triaza Compound Immunoregulatory Agents - The invention provides certain macrocyclic triaza compounds which down-regulate CD4 expression for use in the treatment of autoimmune diseases and inflammatory diseases or conditions. In a specific embodiment, the invention provides certain naphthalene substituted triaza macrocycles which exhibit high activity for down regulation of CD4 expression. In particular, triaza macrocycles having dansyl groups are provided for use in pharmaceutical compositions. | 02-19-2009 |
| 20090054390 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture - This invention relates to methods for providing prognosis of a subjects susceptibility to plaque rupture and compositions for treating plaque rupture and intraplaque hemorrhage. Specifically, the invention is directed to the use of haptoglobin genotyping in determining the susceptibility of a subject to develop intraplaque hemorrhage resulting from plaque rapture and treatment of the intraplaque hemorrhage using antioxidants. | 02-26-2009 |
| 20090062250 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 03-05-2009 |
| 20090069280 | ANALOGS OF BENZOQUINONE-CONTAINING ANSAMYCINS AND METHODS OF USE THEREOF - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 03-12-2009 |
| 20090069281 | Ansamycin formulations and methods of use thereof - Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”). | 03-12-2009 |
| 20090088414 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 04-02-2009 |
| 20090124591 | Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy - The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders. | 05-14-2009 |
| 20090131390 | FK 228 derivates as HDAC inhibitors - Compounds which are FK228 analogues of the general formula (I) or (I′), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R | 05-21-2009 |
| 20090131391 | INHIBITOR FOR DIFFERENTIATION OF HEMATOPOIETIC PRECURSOR CELLS - The invention relates to medicine and can be used for treating persons with diseases associated with a differentiation of hematopoietic precursor cells. The inventive inhibitor for differentiation of hematopoietic precursor cells is embodied in the form of an organic compound of selen-9-phenyl-symmetrical-octahydro-selenoxanten. Said agent makes it possible to more efficiently protect normal tissues. | 05-21-2009 |
| 20090192133 | TREATMENT FOR ACHONDROPLASIA - The present application provides, inter alia, methods of treating disorders mediated by FGFRs and methods of screening for Hsp90 inhibitor compounds. | 07-30-2009 |
| 20090197852 | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor - A method for treating a breast cancer in a subject by administering 17-allylamino-17-demethoxy-geldanamycin (17-AAG) or 17-amino-17-demethoxygeldanamycin (17-AG), or a prodrug of either 17-AAG or 17-AG, in combination with a HER2 inhibitor. | 08-06-2009 |
| 20090209507 | 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies - The present invention relates to 15-O-desmethylmacbecin analogues according to the formula (IA) or (IB) herein, or a pharmaceutically acceptable salt thereof: wherein: R | 08-20-2009 |
| 20090221545 | Ophthalmic Pharmaceutical Composition Containing Amphiphilic Polyaspartamide Copolymers - The present invention relates in general to the use of amphiphilic graft-type copolymers of polyaspartamide for the ophthalmic administration of drugs, such as for example steroidal and non-steroidal anti-inflammatory agents, antimicrobial agents such as aminoglycosides, macrolides, cephalosporin, tetracycline, quinolones, penicillin, beta-lactams, anti-glaucoma agents such as prostaglandins, alpha- and beta-blockers, inhibitors of carbonic anhydrase, cannabinoids, antiviral agents, diagnostic agents, anti-angiogenic agents, antioxidants. | 09-03-2009 |
| 20090253667 | 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer - The present invention relates to 18,21-didesoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pre-treatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies. | 10-08-2009 |
| 20090264397 | HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME - Disclosed are compounds comprising the structure: | 10-22-2009 |
| 20090275546 | Diagnostic tests and personalized treatment regimes for cancer stem cells - Provided are methods of identifying a metabolic target in a cancer stem cell that include using a microarray to identify intracellular signaling networks within a population of cancer stem cells that respond to a growth factor for the stem cell. Also provided are methods of determining a personalized therapeutic regime that include receiving metabolic information relating to a cancer stem cell in a patient, determining the patient's personal criteria relevant to the therapeutic regime, and combining the metabolic and personal criteria. Also provided are a diagnostic test for establishing a personalized therapeutic regime for a colon cancer patient and methods of reducing colon cancer stem cells/treating colon cancer. | 11-05-2009 |
| 20090298804 | Novel Compounds and Methods for Their Production - The present invention relates to 15-desmethoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies. | 12-03-2009 |
| 20090306033 | NOVEL CYCLIC PEPTIDES - Compounds are disclosed of general formula (I): | 12-10-2009 |
| 20090312300 | NOVEL MACROCYCLIC PEPTIDES - Disclosed are cyclosporine derivatives in which the 3-Sarcosine carbon and 5-Valine nitrogen are each substituted by a non-hydrogen substituent, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus. | 12-17-2009 |
| 20100004218 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control fluid and/or waste levels. | 01-07-2010 |
| 20100009953 | CYCLOSPORIN DERIVATIVES FOR TREATING OCULAR AND DERMAL DISEASES AND CONDITIONS - The present invention provides a method for the treatment of ocular or dermal diseases and/or conditions, e.g. an aqueous deficient dry eye state, uveitis or phacoanaphylactic endophthalmitis in an eye, or balanitis, psoriasis, or atopic dermatitis of the skin, said method comprising administering, topically to the eye or the skin, a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: | 01-14-2010 |
| 20100016270 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to improve cardiac and/or cardiovascular health. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control cholesterol levels. | 01-21-2010 |
| 20100022499 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS - Heterocyclic compounds having a relatively flexible backbone are used to create combinatorial libraries that permit screening for lead compounds and selection of drug candidates for a variety of uses in human and veterinary medicine as well as in agriculture. The compounds of the library generally differ in ring size and chirality of substituents on the ring. Also disclosed are methods for providing and screening these libraries, preferably in an automated or computerizable manner, such as by using a computer program to virtually screen the compounds in order to identify those that are predicted to have bioactive conformations that should give rise to desirable biological effects. | 01-28-2010 |
| 20100022500 | Macrocyclic Lactams and Pharmaceutical Use Thereof - The present invention relates to novel macrocyclic compounds of the formula | 01-28-2010 |
| 20100063020 | ORAL PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME - Oral pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, In preferred embodiments, the pharmaceutically active compounds are ansamycins, pharmaceutically acceptable salts, or prodrugs thereof. | 03-11-2010 |
| 20100105647 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES - Disclosed is an amide compound represented by the following formula (1). (1) (In the formula, X | 04-29-2010 |
| 20100152152 | Therapeutic Use of Nefopam - Nefopam is used for the manufacture of a medicament for the treatment of an affective disorder such as ADD or ADHD. | 06-17-2010 |
| 20100179116 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof - The present invention relates to arene connected polyamine macrocyclic derivatives represented by general formula I, pharmaceutically acceptable salts or hydrates thereof which have anti-HIV activities, in which the definitions of substituents are as defined in the description; to preparation methods of the compounds of formula I; to pharmaceutical compositions containing the compounds of formula I or their pharmaceutically acceptable salts or hydrates; to the use of the compounds of formula I or their pharmaceutically acceptable salts or hydrates for the preparation of a medicament for the treatment and prevention of HIV-associated diseases. | 07-15-2010 |
| 20100227842 | METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES - A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis. | 09-09-2010 |
| 20100234338 | CHELATING AGENTS OF METAL IONS, THEIR METHODS OF PREPARATION AND THEIR APPLICATIONS - The present invention relates to compounds that can be used as metal-ion-chelating agents or as depolluting agents, corresponding to general formula (I) below: | 09-16-2010 |
| 20100273762 | Method of combating infection - A method of combating a parasitic protozoal infection of a host organism, the method comprising administering tretazicar to the host organism. Tretazicar is the compound 5-(aziridin- | 10-28-2010 |
| 20100279994 | Ansamycin Formulations and Methods of Use Thereof - The present invention provides pharmaceutical compositions of reduced forms of benzoquinone-containing ansamycins, and salts thereof. The present invention also relates to the use of said pharmaceutical compositions in methods of treating and modulating disorders associated with hyperproliferation, such as cancer. | 11-04-2010 |
| 20100279995 | Novel Ansamycin Derivatives - There are provided inter alia derivatives of a benzenoid ansamycin which contain a 1,4-dihydroxyphenyl moiety bearing at position 6 an amino carboxy substituent, in which position 2 and the carboxy substituent at position 6 are connected by an aliphatic chain of varying length characterised in that one or both of the 1-hydroxy and the 4-hydroxy position(s) of the phenyl ring are independently derivatised by an aminoalkyleneaminocarbonyl group, which alkylene group, which may optionally be substituted by alkyl groups, has a chain length of 2 or 3 carbons and which derivatising group(s) increase the water solubility and/or the bioavailability of the parent molecule but which are capable of being removed in-vivo. Such compounds are described for the treatment of cancer or B-cell malignancies. | 11-04-2010 |
| 20110015168 | METHODS FOR INCREASING LEVELS OF HUMAN FETAL HEMOGLOBIN - The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a β-chain hemoglobinopathy including thalassemia (e.g., β-thalassemia) or sickle cell anemia. | 01-20-2011 |
| 20110021481 | Novel Compounds and Methods for Their Production - The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine. | 01-27-2011 |
| 20110021482 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents - A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula I or Ia: | 01-27-2011 |
| 20110160175 | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer - The present invention relates to macbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pre-treatment for cancer. The present invention also provides methods for the production of these compounds involving incorporation of non-natural starter units and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies. | 06-30-2011 |
| 20110195945 | Compounds, Compositions and Methods for Treating or Preventing Hypoxic or Ischemic Injury - Compositions and methods of treating or preventing disease or injury to a human patient or biological material undergoing ischemic or hypoxic conditions. | 08-11-2011 |
| 20110201587 | HSP90 INHIBITORS AND METHODS OF USE - The present invention provides methods for treating various clinical conditions associated with biological activity of HSP90 in a subject. Such methods include administering to the subject in need of such a treatment a therapeutically effective amount of a composition comprising an HSP90 inhibitor. | 08-18-2011 |
| 20110224184 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS - The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid. | 09-15-2011 |
| 20110257145 | METHOD OF TREATING NEUROLOGICAL DISEASES - A method of treating neurological diseases, like Alzheimer's Disease by administering a compound that activates protein kinase C and inhibits histone deacetylases to an individual suffering from the neurological disease. The method utilizes benzolactam compounds that reduce Aβ production and blocks oxidative stress in the treatment of Alzheimer's disease. The benzolactam compounds and compositions containing the benzolactam compounds also are disclosed. | 10-20-2011 |
| 20110294772 | USE OF CYCLOSQUARAMIDE COMPOUNDS AS ANTI-TUMOUR AGENTS - Use of squaramide-based macrocylic compounds as kinase inhibitor agents and as anti-tumour agents. More specifically, said compounds are used to treat diseases such as cancer, diabetes, neurodegenerative diseases, HIV replication, etc. Furthermore, the present invention likewise relates to pharmaceutical compositions that contain said compounds | 12-01-2011 |
| 20120058982 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 03-08-2012 |
| 20120108562 | THERAPEUTIC COMPOSITIONS AND METHODS - PAD4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention. | 05-03-2012 |
| 20120108563 | Methods Of Treating Liposarcoma - Provided herein are methods of treating liposarcoma in a subject, the method comprising administering to the subject a therapeutically effective amount of an Hsp90 inhibitor. | 05-03-2012 |
| 20120238538 | MACROCYCLIC AMIDES, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF - Macrocyclic amide WH-21091 with antibacterial and antitumor activities, its analogs, preparation methods and uses thereof. The said macrocyclic amides are prepared by microbes of | 09-20-2012 |
| 20120258944 | ANTIOXIDANTS FOR USE IN THERAPY - Compounds based on the following structures: wherein each of R1, R2, R3 and R4 is independently selected from: hydrogen, alkyl, and substituted alkyl; and each of R5, R6 and R7 is independently selected from: hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, N,N-dialkylamino, substituted N,N-dialkylamino, N-monoalkylamino, substituted N-monoalkylamino, and electron-donating substituents are useful in the treatment of disorders or conditions caused by or involving free radical-mediated or oxidative tissue damage. | 10-11-2012 |
| 20130023510 | ARACHIDONIC ACID ANALOGS AND METHODS FOR ANALGESIC TREATMENT USING SAME - The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments. | 01-24-2013 |
| 20130040924 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a bridged polycyclic compound may be pharmaceutically active. In some embodiments, a bridged polycyclic compound may be function as a carrier for pharmaceutically active agents. | 02-14-2013 |
| 20130065872 | SYNTHESIS OF SYRBACTIN PROTEASOME INHIBITORS - The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs. | 03-14-2013 |
| 20130143855 | METHOD TO ALLEVIATE DIABETIC END STAGE RENAL DISEASE - A method of alleviating end-stage renal disease (ESRD), comprising administering an effective amount of a gel-danamycin derivative. | 06-06-2013 |
| 20130203724 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 08-08-2013 |
| 20130244992 | Method of Inhibiting AB-Type Bacterial Toxins and Treatment for Associated Diseases - Disclosed herein are compounds useful in inhibiting the action of AB-type bacterial toxins such as cholera, traveler's diarrhea, enterohemorrhagic diarrhea caused by | 09-19-2013 |
| 20130252932 | LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION - Pharmaceutical preparations, compositions, systems, and devices including medical devices and diagnostic or therapeutic agents, and methods to treat disease by modification of local tissue environment to modulate the therapeutic index of locally or systemically delivered therapeutic or diagnostic agents. Improved ability to reduce sympathetic nerve activity in the adventitia and perivascular tissues around arteries and veins in the body. Modulation of the local tissue environment around an artery to enable more effective denervation with or without a therapeutic agent. Modulation may include adjustment of the pH of the tissue. | 09-26-2013 |
| 20130281423 | METHODS AND COMPOSITIONS FOR AMELIORATING PANCREATIC CANCER - Embodiments of the present invention include methods and compositions for ameliorating cancer. Some embodiments include methods and compositions for ameliorating pancreatic cancer targeting the CXCR4 receptor and the CXCL12 ligand. | 10-24-2013 |
| 20140088063 | AGENTS FOR TREATING NEURODEGENERATIVE DISORDERS - The present invention relates to compounds of formula (I) or (I′), use of these compounds to treat mental disorders, especially depressions of different etiology, and methods for their preparation. The compounds that are provided for the treatment of mental disorders can be presented by a general formula (I) as meso-form—S,2S,1′R,2′R-1-[ω-(3,3-dialkyldiaziridin-1-yl)alkyl]-3,3-dialkyldiaziridines: | 03-27-2014 |
| 20140094444 | COMPOSITIONS AND METHODS FOR TISSUE ENGINEERING AND CELL BASED THERAPIES - The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P | 04-03-2014 |
| 20140187526 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RESPONSIVE TO PROTEASOME INHIBITION - The invention disclosed herein generally relates to methods and compositions for inhibiting proteasome activity comprising a syrbactin compound having the structure of Formula I or II: | 07-03-2014 |
| 20140206658 | SELENO-COMPOUNDS AND THERAPEUTIC USES THEREOF - The present invention relates to compounds and compositions useful as antioxidants and in particular to selenium containing compounds of formula (I): wherein n is 1, 2, or 3; m is 2, 3, 4, or 5; and each R] is independently —(optionally substituted C1-C3 alkylene) p-OH, where p is 0 or 1, or a salt thereof. The invention also relates to the use of these seleno-compounds in the treatment of diseases or conditions associated with increased levels of oxidants produced by myeloperoxidase (MPO), such as for instance, atherosclerosis. | 07-24-2014 |
| 20140303133 | Markers of Triple-Negative Breast Cancer And Uses Thereof - In one aspect provided herein are methods of determining a triple negative breast cancer (TNBC) subtype in an individual in need thereof comprising determining expression of one or more genes in one or more TNBC cells of the individual; and comparing the expression of the one or more genes in the TNBC cells with the expression of the one or more genes in a control. In another aspect, the methods are directed to methods of determining a treatment protocol for the TNBC patient based on the TNBC subtype. In another aspect, the methods are directed to predicting whether an individual will benefit from a treatment for a particular TNBC subtype. In yet another aspect, the invention is directed to a method of determining whether an agent can be used to treat a TNBC subtype. | 10-09-2014 |
| 20140323457 | BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS - The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms. | 10-30-2014 |
| 20140329791 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. | 11-06-2014 |
| 20150025052 | Compositions and Methods for Inhibiting HSP90/HSP70 Machinery - Pharmaceutical compositions including an effective amount of a capsaicin and inhibitors of Hsp90 to decrease or inhibit Hsp70 and Hsp90 chaperone pathways in cells are disclosed. Methods of inhibiting the Hsp70 and Hsp90 chaperone pathways including contacting cells expressing the Hsp70/Hsp90 complex with an effective amount of a capsaicin in combination with inhibitors of Hsp90 to decrease or inhibit the Hsp70 and Hsp90 chaperone pathways are provided. The methods can reduce the viability of target cells, for example, by increasing apoptosis or pro-apoptotic pathways. In preferred embodiments, the methods reduce or do not increase Hsp70, Hsp90, Hsp40, or HOP expression; reduce or do not increase heat shock response; reduce or do not increase pro-survival pathways in cells. Methods of treating cancer and other diseases using the disclosed compositions and methods are provided. | 01-22-2015 |
| 20150051183 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS - The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases. | 02-19-2015 |
| 20150105363 | METHODS AND FORMULATIONS FOR TREATING SCARS AND BETA-CATENIN-MEDIATED DISORDERS - A topical drug composition for treating a β-catenin-mediated disorder in a mammal is provided comprising a Nefopam compound selected from Nefopam, or a functionally equivalent analogue, prodrug, salt or solvate thereof. | 04-16-2015 |
| 20150141392 | SUBSTITUTED MACROCYCLIC COMPOUNDS HAVING PROTEASOME INHIBITORY ACTIVITY - The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors. | 05-21-2015 |
| 20150291538 | Macrocyclic Compositions And Metal Complexes For Bioimaging And Biomedical Applications - The present disclosure provides a novel class of macrocyclic compounds and their metal complexes formed with transition metal ion, lanthanide metal ions and other metal ions (e.g., Al, Ga, Y, In, Sn, Tl, Pb and Bi) and their applications in the fields of contrast agents, artificial nucleases, fluorescence probes, nuclear medicines and other biomedical applications in the therapeutics or diagnostics. | 10-15-2015 |
| 20150306068 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. | 10-29-2015 |
| 20160081980 | Composition Comprising AMD3100 For Preventing or Treating Bone Diseases - The present invention relates to a composition comprising AMD3100 or a pharmaceutically acceptable salt thereof for preventing or treating bone diseases. AMD3100 according to the present invention can effectively prevent or treat of bone diseases by increasing the SDF-1 level in the blood, inducing mobilization of hematopoietic stem/progenitor cell (HSPC) from the bone to the blood, and reducing the deposition of osteoclast on the bone marrow. | 03-24-2016 |
| 20160184257 | ANTIFUGETACTIC AGENTS FOR THE TREAMENT OF PANCREAS CANCER - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 06-30-2016 |
